home / stock / sny / sny articles

SNY Articles, Sanofi - From 12/07/23

Stock Information
Company Name: Sanofi
Stock Symbol: SNY
Market: NASDAQ
Website: sanofi.com
Menu
SNY SNY Quote SNY Short SNY News SNY Articles SNY Message Board
Get SNY Alerts

News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company | Benzinga

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, ...
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities | Benzinga

Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbuster potential (to make over $1 billion in annual sales), ...

IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies | Benzinga

IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agon...

Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis | Benzinga

Merck KGaA (OTC: MKGAF) (OTC: MKKGY) says its two Phase 3 EVOLUTION trials (evolutionRMS 1 and evolutionRMS 2) of evobruti...
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift | Benzinga

Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the...

Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers | Benzinga

European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, includ...

Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder | Benzinga

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic o...
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst | Benzinga

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclo...

US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges | Benzinga

The U.S. Centers for Disease Control and Prevention (CDC) released more than 77,000 additional doses of Beyfortus (nirsevimab), a respira...

Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B | Benzinga

Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health ...
Previous 10 Next 10